Welcome to the UPF Digital Repository

Cost-effectiveness of first-line treatment options and treatment sequencing in advanced renal cell carcinoma

Show simple item record

dc.contributor.author Carson, Brittany
dc.date.accessioned 2020-11-17T16:29:30Z
dc.date.available 2020-11-17T16:29:30Z
dc.date.issued 2020
dc.identifier.uri http://hdl.handle.net/10230/45789
dc.description Master in Health Economics and Pharmaeconomics. (UPF Barcelona School of Management). Curs 2017-2020
dc.description Mentor: Carlos Crespo
dc.description.abstract Continued cancer research allows for the development of novel and potentially superior treatments and management approaches. The recent identification of the role of the immune system in cancer has led to the development of agents targeting the anti-tumor immune response, bringing increased survival and improved patient quality of life. However, these agents, known as immune checkpoint inhibitors (ICIs), also bring additional costs associated with the drug itself and management of immune-associated safety events. Despite the approval of three ICI-based combinations for the first-line treatment of advanced renal cell carcinoma (aRCC), the question remains as to which of the three options is the most cost effective and whether these new agents are more cost-effective overall for society. Further, given that most patients progress on first-line therapy, there is motivation in clinical practice to save ICIs as second-line salvage therapy, retaining the current non-ICI first-line standard of care. A Markov model was created comparing the costeffectiveness of these 3 ICI-based options and the current first-line standard of care in the context of multi-line treatment. The model included direct medical costs, utilities associated with progression-free survival and progressive disease, and commonly used second-line treatment options for patients who progressed on the first-line treatment options. Incremental cost-effectiveness ratios (ICERs) were calculated for all 4 first-line treatment options assessing cost (US dollars) per quality-adjusted life year (QALY). Avelumab + axitinib was the more cost effective first-line option and ICI-based combination. Only nivolumab + ipilimumab exceeded the selected willing-to-pay threshold of $100,000 USD/QALY. In summary, ICI-based combinations, in particular avelumab + axitinib, are also cost-effective first-line options in the treatment of aRCC.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.title Cost-effectiveness of first-line treatment options and treatment sequencing in advanced renal cell carcinoma
dc.type info:eu-repo/semantics/masterThesis
dc.rights.accessRights info:eu-repo/semantics/openAccess


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking